Key Insights

Highlights

Success Rate

76% trial completion

Published Results

54 trials with published results (39%)

Research Maturity

88 completed trials (63% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 74/100

Termination Rate

20.1%

28 terminated out of 139 trials

Success Rate

75.9%

-10.6% vs benchmark

Late-Stage Pipeline

4%

5 trials in Phase 3/4

Results Transparency

61%

54 of 88 completed with results

Key Signals

54 with results76% success28 terminated

Data Visualizations

Phase Distribution

133Total
Not Applicable (18)
Early P 1 (1)
P 1 (53)
P 2 (56)
P 3 (4)
P 4 (1)

Trial Status

Completed88
Terminated28
Withdrawn7
Active Not Recruiting6
Recruiting6
Unknown4

Trial Success Rate

75.9%

Benchmark: 86.5%

Based on 88 completed trials

Clinical Trials (139)

Showing 20 of 20 trials
NCT02390427Phase 1Completed

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

NCT02226276Not ApplicableActive Not Recruiting

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

NCT01953588Phase 3Active Not Recruiting

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

NCT04360941Phase 1Recruiting

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

NCT06369285Phase 2Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT01722851Completed

Circulating miRNAs.

NCT06570031Phase 1Active Not Recruiting

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

NCT05891197Terminated

A Biomarker Screening Protocol for Participants With Solid Tumors

NCT05274451Phase 1Terminated

A Study to Investigate LYL797 in Adults With Solid Tumors

NCT01819233Not ApplicableCompleted

Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy

NCT01730833Phase 2Active Not Recruiting

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

NCT01824836Not ApplicableActive Not Recruiting

A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

NCT01938833Phase 1Terminated

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

NCT06900647Phase 1Recruiting

Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

NCT06202118Not ApplicableRecruiting

A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients.

NCT02203552Phase 2Completed

Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer

NCT03530696Phase 2Completed

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

NCT01706432Completed

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

NCT01791478Phase 1Active Not Recruiting

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

NCT06329089RecruitingPrimary

Reoperative Sentinel Lymph Node Biopsy in Patients With Recurrent Ipsilateral Breast Cancer

Scroll to load more

Research Network

Activity Timeline